Most trials are still ongoing and only one prospective randomized clinical trial with a primary outcome of major cardiovascular events in patients with T2D has reported its results [28]
A systematic review of multiple studies shows that weight regain is a common outcome
Understanding the specific metabolic alterations within each major etiology is key to target the disease with a compound, which can help metabolic homeostasis, such as GLP-1 R analogs (Wang and Lu, 2025
Moreover, use of dulaglutide in people with T2DM is likely to confer additional renal benefits, and dulaglutide may be used in advanced chronic kidney disease at any eGFR level and without dose adjustment in contrast with most other noninsulin diabetes therapies (134, 135)
In fact, uncontrolled diabetes is one of the leading causes of kidney failure, and many diabetes medications actually help protect kidney function
After experiencing firsthand the life-changing benefits of medically supervised GLP-1 weight loss treatment, Dr
